NewGenIvf
NIVF
3 hedge funds and large institutions have $41.7K invested in NewGenIvf in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
39% less capital invested
Capital invested by funds: $68.8K → $41.7K (-$27.1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$87.3K |
| 2 |
VF
Virtu Financial
New York
|
+$87.3K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$29.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MG
Marex Group
London,
|
-$7.49K |
| 2 |
Two Sigma Investments
New York
|
-$6.64K |
| 3 |
HF
HRT Financial
New York
|
-$4K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
-$406 |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$7 |
NIVF Hedge Fund Activity: Q1 2025 in Review
3 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in NewGenIvf (NIVF) for Q1 2025, worth a combined $41.7K — down 39% from $68.8K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NIVF positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $87.3K. The largest seller was Marex Group, cutting an estimated $7.49K.
- 3 institutional investors held NewGenIvf (NIVF) as of Q1 2025, up from 0 in Q4 2024.
- Funds reported $41.7K of NewGenIvf stock for Q1 2025, down 39% quarter-over-quarter.
- 3 funds opened new NewGenIvf positions in Q1 2025 and 0 closed out, a net change of +3 holders.
- The largest NewGenIvf buyer in Q1 2025 was Citadel Advisors, an estimated $87.3K added.
- The largest NewGenIvf seller in Q1 2025 was Marex Group, an estimated $7.49K sold.
Based on aggregated 13F filings for Q1 2025.